🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Huge thanks to Elliot Tapper for sharing our METCon_Consortium paper out now in Hepatology Communications l!

#T2DM is a significant factor contributing to the progression of fibrosis in #MASLD Daniel Huang #APASL2025 APASL News

Thanks APASL News for the invitation to discuss MASH HCC and the oral plenary session on #MASH therapeutics. Great to see many old friends and new ones Dr.Bornie Dr Nipun Verma Sak Chirapongsathorn, M.D. loeymak Terry Cheuk-Fung Yip Mark Muthiah

Excited to talk about #AI in #HCC prediction🔮 Bright future✨ Enjoyed the fruitful discussion! #APASL2025 APASL News CUHK Medicine CUHK Gastroenterology & Hepatology

"Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort" now available to read 'open access' via bit.ly/4i5Wz62 #livertwitter #HCC #atezolizumab #bevacizumab

A 67-Year-Old Donor’s ‘Sliver of Liver’ Saves a Baby’s Life chla.org/blog/patients/… Children's Hospital LA Kambiz Etesami, MD, FACS

🧵1/10 🚨 First-ever global guidelines for managing MASLD in T2DM are here! Grateful to anoop misra for leading this effort and for including me as a co-author. This thread summarizes key takeaways that can guide physicians in managing these patients. authors.elsevier.com/c/1kwHL6fWV2v7…

Our MASLD Research Center new paper on Change in cT1 following Rx in MASLD: A systematic review and meta-analysis FGF-21-📉cT1 of -79ms, GLP-1-📉cT1-68ms Placebo- cT1-0 pubmed.ncbi.nlm.nih.gov/40220846/ EASLnews AASLD ACG Daniel Huang Quentin M. Anstee Manuel Romero-Gómez Christopher A. Longhurst, MD

Read the 15th May 2025 issue of roypounder.apt via bit.ly/4jIbyEa #clinicaltrial #IBD #coeliac #PSC #cirrhosis #HBV #HCC #oesophagus

🚨 #liverTwitter Just out! Our meta-analysis of 17.6M patients shows #SLD subtypes carry distinct risks with #MetALD & #ALD having an 📈risk of mortality, liver related events and CVD events Pojsakorn Dan Danpanichkul, MD Daniel Huang Mazen Noureddin, MD, MHSc Karn Wijarnpreecha sciencedirect.com/science/articl… #LiverTwitter

🇬🇧 CALIBRE trial – D. Tripathi at #EASL2025 RCT: carvedilol vs VBL for 1º prevention in cirrhosis 🟰 No difference in bleeding or survival at 12 months 💊 Carvedilol safe, simpler & cost-effective 📉 Follow-up limited (12 mo), but extension planned ⚠️ Underpowered due to COVID

📢 The updated #HBV guidelines were just presented by Markus Cornberg @ #EASLcongress. ✔️ Focus on shared decision-making ✔️ Simplified treatment algorithm ✔️ Clear answers to key questions: 👉Who to treat? 👉When to start? 👉What are the #HCC risk factors? 👉What if ALT is

Original Article: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY trial) nej.md/4kru98f EASLnews | #EASLCongress

Important changes in clinical practice for treating people with HBV! Impressive work from EASLnews Grace Wong and colleagues

Prescribing therapies for MASH but unsure of treatment response? The MASH Resolution Index, or FAST score may be helpful 🔥off the press HEPATOLOGY Journal Rohit Loomba AASLD journals.lww.com/hep/abstract/9…

In this international, collaborative effort led by Douglas Chee, we estimate the presence of health policies directed at reducing the burden of HCC CGH American Gastroenterological Association (AGA) Jörn Schattenberg Cheng Han Ng Arndt Vogel Yong Loo Lin School of Medicine Rashid Lui 雷諾信 Jimmy Che-To Lai cghjournal.org/article/S1542-…

📢 It’s OVER. The “lean MASLD paradox”? Just bad measurement. ❎MASLD with overweight BMI weren’t healthier! We were using the wrong metric. ↗️Waist circumference-related indices show a dose-dependent mortality risk across 3 prospective cohorts. Let’s reframe how we assess

Check out our article in Nature Reviews Gastroenterology & Hepatology where we discuss oncogastroenterology- “The growing need to manage the digestive and liver health of patients with cancer, together with the increasing global cancer burden, provide a strong rationale for the convergence of the

Congrats Alfred Kow Mark Muthiah on a successful #ilts2025 launch! ILTS

Feasting on science and good food ILTS - thanks for the invitation to discuss MASH HCC and grateful for the opportunity to meet old and new friends #ILTS2025 NUCDigest Anand V Kulkarni James Fung, MD, FAASLD, FRACP Chanda Ho Ek Khoon Tan